metaEvidence - overview

benefit
(statisticaly significant)

benefit (nominaly significant, not statitically demonstrated)

not significant

harm statitically significant

harm not significant

low certainty due to bias


			deaths (OS)	progression or deaths (PFS)	RFS/DFS
mNSCLC - L1 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - PDL1 positive
versus Standard of Care (SoC)
	atezolizumab alone vs. Standard of Care (SoC)	3			-
	cemiplimab vs. Standard of Care (SoC)	1			-
	durvalumab alone vs. Standard of Care (SoC)	1			-
	nivolumab alone vs. Standard of Care (SoC)	2			-
	pembrolizumab alone vs. Standard of Care (SoC)	4			-